Quando la nostra scelta fa la differenza: la gestione dell’emergenza

Presentazione sul tema: "Quando la nostra scelta fa la differenza: la gestione dell’emergenza"— Transcript della presentazione:

1 Quando la nostra scelta fa la differenza: la gestione dell’emergenza
PhD, MD Sergio Agosti Dirigente medico SOC Cardiologia Ospedale Novi Ligure

2 “Storytelling is the most powerful way to put ideas
into the world today” Docente di sceneggiatura, padre dei principali scenografi di Holliwood, autore della Bibbia degli scenografi “Story” Robert McKee Screenwriting Lecturer

3 Luciano Maria Giacomo

4 Caso clinico 1 Luciano, 83 anni
Iperteso, IRC, iniziale decadimento cognitivo FANV permanente, portatore di PM Dabigatran 110 mg BID Ricoverato in Medicina per diagnosi di “scompenso cardiaco” Caduta a terra accidentale con trauma cranico ed ematoma subdurale

5 Caso clinico 1 Somministrato Idarucizumab 5 gr ev per antagonizzare effetto Dabigatran (aPTT 44 sec) Intervento neurochirurgico per evacuazione ematoma subdurale Crisi comiziali post chirurgiche, iniziato Levitiracetam 500 mgx2 Dimesso dopo 15 giorni in discrete condizioni, in terapia con LMWH

6 Caso clinico 2 Maria, 71 anni Ipertesa FANV parossistica
Dabigatran 150 mg BID Si presenta in DEA per emiparesi destra ed afasia insorta da 2 ore Ictus emisferico sinistro (NIHSS 9) TIA, NIHSS <8 lieve, NIHSS 8-14 moderato, NIHSS >14 grave J Med Case Rep, 2017 Aug 15; 11:224. Agosti S et al.

7 Caso clinico 2 Somministrato Idarucizumab
5 gr ev per antagonizzare effetto Dabigatran Somministrata terapia trombolitica (Alteplase 0.9 mg/kg) Paziente non aveva assunto dose di DOAC del mattino (aPTT 29 sec) Completo ripristino della capacità motoria e parziale miglioramento afasia J Med Case Rep, 2017 Aug 15; 11:224. Agosti S et al.

8 Oggi lasciate che vi racconti una storia, anzi due

9 19 ischemie cerebrali in dabi, trattate con antidoto e successivamente trombolisi
Int J Stroke Jun;12(4):

10 Caso clinico 3 Giacomo, 82 anni Lesioni da decubito al sacro e tallone
Diabete mellito tipo 2 Portatore di PM FANV permanente Dabigatran 110 mg BID Si presenta in DEA per febbre (39°C) e progressiva riduzione dello stato di coscienza fino al coma (GCS 3) Uomo che viveva in casa di riposo Under revision. J Clin Case Rep, Agosti S et al.

11 Caso clinico 3 Nel sospetto di meningite somministrato Idarucizumab 5 gr ev per antagonizzare effetto Dabigatran 15 minuti dopo effettuata puntura lombare senza complicanze emorragiche, poi risultata negativa 16 ore dopo è stato reiniziato Dabigatran Uomo che viveva in casa di riposo Paziente è deceduto 11 giorni dopo per shock settico da staphylococcus aureus Under revision. J Clin Case Rep, Agosti S et al.

12 All anticoagulants can cause bleeding
Concetto che può sembrare ovvio ma non è banale

13 Challenges in bleeding
Management of bleeding - Prevention - Treatment (….antidotes) sfide

14 NOACs associated with a non significant RRR of 14%
MAJOR BLEEDING No head to head comparisons NOACs associated with a non significant RRR of 14% compared to Warfarin Ruff CT, Lancet, December 4, 2013

15 60% RRR Haemorrhagic stroke
Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta analysis Daniel Caldeira et al. J Neurol 2014

16 "The unthinkable has become conceivable”
David Baltimore David Baltimore premio nobel nel 1975 insieme a Renato Dulbecco, per ricerca su relazione tra i virus e i tumori.

17 Haemorrhagic stroke (TF receptor)
Tissue factor (TF) is a transmembrane receptor for Factor VII/VIIa (FVII/VIIa). It is constitutively expressed by cells surrounding blood vessels. The endothelium physically separates this potent "activator" from its circulating ligand FVII/FVIIa and prevents inappropriate activation of the clotting cascade. Breakage of the endothelial barrier leads to exposure of extravascular TF and rapid activation of the clotting cascade. TF is also expressed in certain tissues, such as the heart and brain, and provides additional hemostatic protection to these tissues. Il Fattore tissutale, noto più propriamente come Tissue Factor (TF) ed altrimenti indicato come fattore III o CD142, è una glicoproteina presente nel tessuto subendoteliale, nelle piastrine, e nei leucociti necessaria per la formazione della trombina dal suo zimogeno: la protrombina. La formazione della trombina porta alla coagulazione del sangue. Il tissue factor non va confuso con la tromboplastina, che è infatti un estratto tissutale composto quasi esclusivamente da TF e fosfolipidi anionici. Le diverse tromboplastine in commercio, che differiscono in termini di attività pro-coagulante, sono comunemente utilizzate in laboratorio per effettuare test di screening dell'emostasi. Mackmann, Anesth Analg May; 108(5): The role of tissue factor and factor VIIa in hemostasis.

18 Modifiable and non-modifiable risk factors
for bleeding in anticoagulated patients based on bleeding risk scores ESC Guidelines 2016

19 Choosing the right dose
Riduzione della dose preserva efficacia e aumenta sicurezza, fino al 30% dei pz non riceve una dose appropriata… sptt sottodosata ma anche sovradosata…. Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atriale fibrillation-related stroke prevention. Camm AJ, Fox KAA, Peterson E. Europace Oct 13.

20 Challenges in bleeding
Management of bleeding - Prevention - Treatment (….antidotes) sfide

21 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

22 Idarucizumab was designed as a specific reversal agent for the anticoagulant activity of dabigatran
Humanized Fab fragment Binding affinity for dabigatran ~350× higher than dabigatran to thrombin IV administration, immediate onset of action Short half-life Idarucizumab is a humanized antibody fragment that binds to dabigatran with a more than 350-fold higher affinity than dabigatran does to thrombin, thus preventing dabigatran from binding to thrombin and so reversing its anticoagulant effects. Humanization of the antibody fragment and the removal of the Fc region reduce the immunogenic potential of the molecule. The antibody fragment does not bind to known thrombin substrates and has no activity in coagulation tests or platelet aggregation, and thus has no procoagulant or anticoagulant effects on its own. Due to its intravenous application route, idarucizumab has a fast onset of action. Idarucizumab has a half-life of approximately 6 hours. It binds rapidly to dabigatran and the antidote–dabigatran complex is eliminated quickly. This potentially allows a patient to resume dabigatran treatment soon after the bleeding event has been resolved. Idarucizumab has no known endogenous targets. It is highly specific to dabigatran, which has no naturally occurring homologues in the human body. References Schiele F et al. Blood 2013;121: Stangier J et al. OR 320; presented at ISTH 2015 No intrinsic procoagulant or anticoagulant activity Adapted from Schiele F et al. Blood 2013; Stangier J et al. ISTH 2015, OR320

23 N Engl J Med, 11 July 2017; 377:431-41

24 RE-VERSE AD™ is a multicentre, open-label, single-arm Phase III trial
Group A: Uncontrolled bleeding + dabigatran-treated 301 pt Group B: Emergency surgery or procedure* + dabigatran-treated 202 pt N=503 0–15 minutes 90 days’ follow-up 0–24 hours 2x2.5 g idarucizumab Hospital arrival Pre-2nd dose 2 h 4 h 12 h 24 h 30 d 90 d Pre-1st dose 1 h Blood samples ~20 min Pollack C et al. Thromb Haemost 2015;114:198–205 Idarucizumab e andexanet hanno ricevuto da FDA la designazione a Breakthrough Therapy Designation, cioè terapia rivoluzionaria, ciò consente un percorso di approvazione accelerato (6 mesi) Efficacy Endpoint Maximum reversal of dabigatran’s activity, based on central laboratory measurements of dTT or ECT from end of first infusion up to 4 hours after completion of last infusion Pollack et al. Thromb Haemost 2015

25 RE-VERSE AD results (Primary Outcome)
Group A: Uncontrolled bleeding Group B: Emergency surgery or procedure Immediate and complete reversal: evident even after the first vial of idarucizumab Idarucizumab 2×2.5 g dTT (s) dTT (s) Adapted from Pollack CV et al.1 These figures show the primary endpoint of RE-VERSE AD™ – reversal of dabigatran anticoagulation – for the Group A patients, who have uncontrolled bleeding, and the Group B patients, who required urgent reversal of anticoagulation for emergency surgery or procedures. The results show immediate reversal of anticoagulation after administration of the first idarucizumab vial, demonstrated by dTT assay, and sustained through 24 hours in most patients. In Group A, the median maximum percentage reversal within 4 hours was 100%. Looking at normalization of individual coagulation tests, dTT was normalized in 98% of evaluable patients. ECT assays also showed immediate reversal, sustained through 24 hours in most patients. ECT was normalized in 89% of evaluable patients. In Group B, the median maximum percentage reversal was 100%. Looking at normalization of individual coagulation tests, dTT was normalized in 93% of evaluable patients. ECT assays also showed immediate reversal, sustained through 24 hours in most patients. ECT was normalized in 88% of evaluable patients. Data are presented as box and whisker plots where the top and bottom of the rectangles reflect the 75th and 25th percentiles, respectively; the horizontal lines within the rectangles reflect the 50th percentile; and the horizontal lines above and below the rectangles reflect the 90th and 10th percentiles, respectively. Reference Pollack CV et al. N Engl J Med 2015;373:511–20 Time post-idarucizumab Time post-idarucizumab Similar results were also demonstrated with ECT, aPTT N Engl J Med, 11 July 2017; 377:431-41

26 Indications for Dabigatran Reversal
With a median time to bleeding cessation of: 2.5 hrs N Engl J Med, 11 July 2017; 377:431-41

27 Indications for Dabigatran Reversal
N Engl J Med, 11 July 2017; 377:431-41

28 Group B: most patients had normal haemostasis during surgery
Periprocedural haemostasis was classed as: 1.5% 93.4% 5% Normal Mildly abnormal Moderately abnormal 1.6 hrs Overall median time from first vial to procedure: N Engl J Med, 11 July 2017; 377:431-41

29 Specific Antidotes for NOACs
Ciraparantag… antidoto per tutti i nao Yoonsun Mo, Felix K. Yam. Pharmacotherapy 2015;35(2):198–207

30 Conclusioni Antidoto: importante novità scientifica e clinica
Migliora ulteriormente profilo di sicurezza dei DOAC (Dabigatran) Qualsiasi situazione Pazienti in triplice o duplice terapia Pazienti con HASBLED>4 non modificabile Pregressa emorragia maggiore

31 GRAZIE PER L’ATTENZIONE